Every year, the American Society of Clinical Oncology (ASCO) Annual Meeting highlights some of the most important advances in cancer research and treatment. ASCO 2026 was no exception, with new clinical trial data and expert discussions offering valuable insights into how cancer care may evolve in the years ahead.
For breast cancer, several presentations stood out for their potential impact on patient care. Key themes included expanding treatment options for metastatic breast cancer, refining risk-based treatment decisions in early-stage disease, and growing evidence that some patients may achieve excellent outcomes with less intensive therapy. Together, these findings reflect the ongoing shift toward more personalized, patient-centered care.
While many of these results are promising, not all will immediately change clinical practice. In Canada, new treatments and testing strategies must still undergo regulatory review and funding assessments before becoming widely available. Even so, the studies presented at ASCO 2026 provide an important look at where breast cancer treatment is headed — and which developments clinicians and patients will be watching most closely in the months ahead.
Metastatic TNBC
The TROPION Breast02 study showed datopotamab deruxtecan improved both progression free and overall survival compared with chemotherapy for people with metastatic TNBC who are not candidates for immunotherapy.
Metastatic TNBC
The ASCENT 03 study showed sacituzumab govitecan improved progression free survival compared with chemotherapy in first line metastatic TNBC for people who are not candidates for checkpoint inhibitors.
HR+ MBC
The SERENA 6 study used circulating tumor DNA to detect ESR1 mutations early and switch treatment before scans showed progression. Camizestrant significantly improved progression free survival compared with staying on standard endocrine therapy. This could reshape how liquid biopsies are used in metastatic breast cancer care.
PIK3CA mutated MBC
Updated INAVO120 data continued to support the benefit of adding inavolisib to palbociclib and fulvestrant for people with PIK3CA mutated HR positive HER2 negative metastatic breast cancer. Researchers are increasingly viewing this combination as a potential future standard in this subtype.
HR+ ESR1 mutated MBC
VERITAC 2 highlighted vepdegestrant, a new estrogen receptor degrader that showed improved progression free survival compared with fulvestrant, particularly in ESR1 mutated disease. This adds momentum to a growing wave of oral endocrine therapies designed to overcome resistance.
HR+/HER2- MBC
Research exploring treatment de escalation strategies, such as the VICTORIA trial, continues to gain momentum. As more people are living longer with metastatic breast cancer, approaches that may help reduce side effects while maintaining outcomes are increasingly meaningful from a quality of life perspective.
Early-stage surgery de-escalation
The SENOMAC trial found that some patients with limited spread to sentinel lymph nodes may safely avoid axillary lymph node dissection, reducing the risk of long-term arm complications.
HER2 positive early breast cancer chemotherapy de-escalation
New analyses presented at ASCO continued to support treatment de-escalation strategies in HER2 positive early breast cancer, including efforts to safely reduce chemotherapy intensity for some patients while maintaining excellent outcomes. The goal is not just curing more people, but reducing long term toxicity too.
CDK4/6 inhibitors in early breast cancer
Updated NATALEE data continued to reinforce the benefit of ribociclib in stage II and III HR positive HER2 negative early breast cancer, including across different ages and menopausal groups. Researchers are continuing to refine which patients may benefit most from extended therapy.
Early-stage TNBC
Long term follow up from KEYNOTE-522 continued to show a major survival benefit from adding pembrolizumab (Keytruda) to chemotherapy before surgery, followed by pembrolizumab after surgery in high-risk early stage TNBC.
Early-stage HR+/HER2-
New phase III data from the OPTIMA Trial suggest some people with early stage breast cancer may be able to safely avoid chemotherapy based on genomic testing. This is another important step toward more personalized treatment and reducing unnecessary toxicity when chemo may not provide meaningful benefit.
Early-stage HER+ breast cancer
Emerging research is continuing to refine how treatments are matched to tumour biology and patient characteristics, reinforcing the movement toward more individualized cancer care. The IRIS-A trial evaluated adjuvant capecitabine plus trastuzumab.
ASCO 2026 highlighted meaningful progress across the breast cancer landscape, from new treatment options in metastatic disease to more personalized approaches in early-stage care. While many of these advances will take time to reach patients in Canada, they represent important steps toward better outcomes, fewer side effects, and more individualized treatment.
We’ll be watching these developments closely as the latest breast cancer research continues to shape the future of care and will keep the community updated on the latest treatment news!